Radiosensitizers in Hepatocellular Carcinoma

Ik Jae Lee, Jinsil Seong

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Most hepatocellular carcinoma (HCC) patients present with locally advanced disease with a risk of development of intrahepatic or extrahepatic metastases. Conformal radiotherapy (RT) can be delivered to focal HCCs with sustained local control in selected HCC patients. However, it is frequently not possible to deliver tumoricidal doses to locally advanced HCC due to the risk of radiation-induced liver toxicity or the risk of toxicity to adjacent luminal gastrointestinal organs. Combining RT with radiosensitizers is an attractive strategy to increase the therapeutic ratio for these patients. Clinical experience in combining RT and radiosensitizers in HCC is limited. Hepatic arterial chemoembolization (or transcatheter arterial chemoembolization, TACE) has been used in combination with RT for the treatment of HCC, as have halogenated pyrimidines. More recently, there is a growing experience of RT delivered with molecular targeted agents in HCC. In this review, the rationale for potential radiation sensitization and the clinical experience in HCC for different classes of radiation sensitizers are discussed.

Original languageEnglish
Pages (from-to)303-311
Number of pages9
JournalSeminars in Radiation Oncology
Volume21
Issue number4
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Radiation
Radiation-Sensitizing Agents
Conformal Radiotherapy
Pyrimidines
Liver
Neoplasm Metastasis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{685d7e088c8744ba88f4c733e2bc869c,
title = "Radiosensitizers in Hepatocellular Carcinoma",
abstract = "Most hepatocellular carcinoma (HCC) patients present with locally advanced disease with a risk of development of intrahepatic or extrahepatic metastases. Conformal radiotherapy (RT) can be delivered to focal HCCs with sustained local control in selected HCC patients. However, it is frequently not possible to deliver tumoricidal doses to locally advanced HCC due to the risk of radiation-induced liver toxicity or the risk of toxicity to adjacent luminal gastrointestinal organs. Combining RT with radiosensitizers is an attractive strategy to increase the therapeutic ratio for these patients. Clinical experience in combining RT and radiosensitizers in HCC is limited. Hepatic arterial chemoembolization (or transcatheter arterial chemoembolization, TACE) has been used in combination with RT for the treatment of HCC, as have halogenated pyrimidines. More recently, there is a growing experience of RT delivered with molecular targeted agents in HCC. In this review, the rationale for potential radiation sensitization and the clinical experience in HCC for different classes of radiation sensitizers are discussed.",
author = "Lee, {Ik Jae} and Jinsil Seong",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.semradonc.2011.05.008",
language = "English",
volume = "21",
pages = "303--311",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Radiosensitizers in Hepatocellular Carcinoma. / Lee, Ik Jae; Seong, Jinsil.

In: Seminars in Radiation Oncology, Vol. 21, No. 4, 01.10.2011, p. 303-311.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radiosensitizers in Hepatocellular Carcinoma

AU - Lee, Ik Jae

AU - Seong, Jinsil

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Most hepatocellular carcinoma (HCC) patients present with locally advanced disease with a risk of development of intrahepatic or extrahepatic metastases. Conformal radiotherapy (RT) can be delivered to focal HCCs with sustained local control in selected HCC patients. However, it is frequently not possible to deliver tumoricidal doses to locally advanced HCC due to the risk of radiation-induced liver toxicity or the risk of toxicity to adjacent luminal gastrointestinal organs. Combining RT with radiosensitizers is an attractive strategy to increase the therapeutic ratio for these patients. Clinical experience in combining RT and radiosensitizers in HCC is limited. Hepatic arterial chemoembolization (or transcatheter arterial chemoembolization, TACE) has been used in combination with RT for the treatment of HCC, as have halogenated pyrimidines. More recently, there is a growing experience of RT delivered with molecular targeted agents in HCC. In this review, the rationale for potential radiation sensitization and the clinical experience in HCC for different classes of radiation sensitizers are discussed.

AB - Most hepatocellular carcinoma (HCC) patients present with locally advanced disease with a risk of development of intrahepatic or extrahepatic metastases. Conformal radiotherapy (RT) can be delivered to focal HCCs with sustained local control in selected HCC patients. However, it is frequently not possible to deliver tumoricidal doses to locally advanced HCC due to the risk of radiation-induced liver toxicity or the risk of toxicity to adjacent luminal gastrointestinal organs. Combining RT with radiosensitizers is an attractive strategy to increase the therapeutic ratio for these patients. Clinical experience in combining RT and radiosensitizers in HCC is limited. Hepatic arterial chemoembolization (or transcatheter arterial chemoembolization, TACE) has been used in combination with RT for the treatment of HCC, as have halogenated pyrimidines. More recently, there is a growing experience of RT delivered with molecular targeted agents in HCC. In this review, the rationale for potential radiation sensitization and the clinical experience in HCC for different classes of radiation sensitizers are discussed.

UR - http://www.scopus.com/inward/record.url?scp=80052990379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052990379&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2011.05.008

DO - 10.1016/j.semradonc.2011.05.008

M3 - Review article

VL - 21

SP - 303

EP - 311

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 4

ER -